Life Sciences Snapshot – A Quarterly Report on Financing Trends – Q2 2021
22 minute read | April.20.2021
Record-breaking Markets and a Candid Conversation on University Spinouts
This edition of Orrick’s series of life sciences publications breaks down the drivers of record venture investment into US-based life sciences companies last year. Key findings include:
US-based life sciences companies closed 465 venture deals in Q1 2021 for a quarterly record value of $12.2 billion. Even more so than in past years, the promise of personalized medicine seems more feasible, given increasingly powerful diagnostic platforms and the explosion in home-based point-of-care virtual health and testing kits for general health concerns.
Investors are plowing into the sector with such fervor that deal sizes and valuations are all marking new highs, even given significant growth in the past few years.
Liquidity remains strong, with the sector securing $17.4 billion across 51 events in Q1 2021; the SPAC phenomenon has begun to yield a handful of exits for life sciences companies.
Investment levels will likely sustain, as all indicators continue to remain promising, from the macro to the cyclical.
Please do not include any confidential, secret or otherwise sensitive information concerning any potential or actual legal matter in this e-mail message. Unsolicited e-mails do not create an attorney-client relationship and confidential or secret information included in such e-mails cannot be protected from disclosure. Orrick does not have a duty or a legal obligation to keep confidential any information that you provide to us. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.
By clicking "OK" below, you understand and agree that Orrick will have no duty to keep confidential any information you provide.